August 2023 Global Innovative Drug Report

2023-09-18T13:36:30Z

Z2vxwus221: Ak: Uusi sivu: Our August 2023 drug report offers an in-depth look into the pharmaceutical industry’s recent innovations, diving deep into individual drug analyses. Within, you’ll find details on each drug’s profile, R&D status, active patents, mechanisms of action, clinical trials, competitive dynamics, and more. This report consists of four parts: August new drug approvals New drug analysis Global drugs under Expedited Review Pathway Analysis of selected ERP drugs Report Ove...

Our August 2023 drug report offers an in-depth look into the pharmaceutical industry’s recent innovations, diving deep into individual drug analyses. Within, you’ll find details on each drug’s profile, R&D status, active patents, mechanisms of action, clinical trials, competitive dynamics, and more.

This report consists of four parts:

August new drug approvals

New drug analysis

Global drugs under Expedited Review Pathway

Analysis of selected ERP drugs

Report Overview

1.) August Drug Approvals

In August 2023, a total of nine drugs received global approval. This included three monoclonal antibodies, two bispecific [https://eureka.patsnap.com/patent-CN106440548A Improve discharge performance] antibodies, two small molecule drugs (SMDs), one RNA vaccine, and one aptamer drug conjugate.

August 2023 Global Approved Drugs, Synapse

2.) New Drug Analysis

This report features in-depth analyses of five newly approved drugs, including a thorough examination of Avacincaptad pegol.

Avacincaptad pegol treats the severe eye condition known as geographic atrophy. It aims to delay vision deterioration by preventing the immune system from damaging eye cells.

Avacincaptad pegol Snapshot & R&D Status, Patsnap Synapse

Avacincaptad pegol Active Patent & Analysis, Patsnap Synapse

Avacincaptad pegol Analysis Continued, PatSnap Synapse

Avacincaptad pegol Analysis Continued, Patsnap Synapse

3.) Global Drugs Under Expedited Review Pathway

What’s more, 56 drugs were placed on ERP in August, including 35 orphan drug designations, nine with fast track status, four targeting rare pediatric diseases, three [https://eureka.patsnap.com/patent-CN1422901A Input technology] under breakthrough therapy designation, three with priority reviews, two receiving accelerated approvals, and one granted conditional marketing approval.

August 2023 Global Drugs Subject to Expedited Review, Synapse

4.) Analysis of Selected ERP Drugs

This report also highlights five ERP drugs for detailed analysis. Focusing on Savolitinib — a receptor tyrosine kinase inhibitor targeting the mesenchymal-epithelial transition factor (MET), here’s what we uncovered:

Savolitinib Snapshot & R&D Status & Active Patent, PatSnap Synapse

Savolitinib Snapshot & R&D Status & Active Patent, Patsnap Synapse

Savolitinib Analysis, Patsnap Synapse

Savolitinib Analysis, Patsnap Synapse

Gain Access to the Comprehensive Report for FREE – Download Now! If you aren’t registered for Synapse (registration is required to download the report), click here to register for free.

Get the Report

Patsnap Synapse Database: An Overview and Key Features

Discover the innovative PatSnap Synapse database – an AI-powered platform that provides intuitive interfaces, curated content, and access to massive information sources. With integrated access to company data, diseases, targets, clinical studies, and biological and chemical entities, our platform offers a powerful search and association experience. Sign up for free today [https://eureka.patsnap.com/patent-CN109324647A Ethyl-phenol] and experience the benefits for yourself!

R&D Decision Makers

Our mission is to empower R&D decision makers with swift access to accurate and connected data, facilitating their understanding of emerging technology trends, competitive landscapes, and partnership opportunities. By providing comprehensive insights, our platform helps [https://eureka.patsnap.com/patent-CN103972506A Department pediatrics] decision makers to navigate and steer the direction of innovation with confidence.

Business Development Professionals

We offer a comprehensive database that covers the drug pipeline and investment history for over 320,000 life science organizations. This invaluable resource allows you [https://eureka.patsnap.com/patent-CN114040816A Platinum black] to make informed decisions regarding potential partnerships or acquisition targets with confidence. Gain access to our extensive database and unlock the insights you need to drive your business forward.

Pharmaceutical Analyst

Our platform is designed to accelerate the research process for pharmaceutical analysts by leveraging a wealth of connected data, including drug approvals, clinical trials, patents, non-patent literature, and news. With Synapse, users gain a comprehensive 360-degree view of the competitive and technological landscape, empowering them to make informed decisions quickly and efficiently. Discover the power of Synapse and revolutionize your research today.

Copyright Statement: This report is the sole property of Patsnap and is protected under copyright laws. Any reproduction, excerpting, or other use of this report without explicit authorization from Patsnap is strictly prohibited. Authorized products must be used within the scope of authorization and must include a clear indication of the source. Patsnap reserves the right to investigate any violations of this statement and pursue legal action as necessary. For inquiries regarding authorization

Motopedia - Käyttäjän muokkaukset [fi]

August 2023 Global Innovative Drug Report